PharmaRadar360

PharmaRadar360

🌍·Aug 25discovery

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

Publisher

T
The Manila Times

Global

This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
The Manila Times
Region
Global
Scope
discovery
Published
August 25, 2026
Language
EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on news.google.com

Leave the platform to read the original full article on the publisher site.

Source: The Manila Times

Scope: discovery

Open original article
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026 | PharmaRadar360